Press Releases

Date Title View
Toggle SummaryJune 29, 2020 GenMark Diagnostics Announces Commercial Launch of its ePlex® Respiratory Pathogen Panel 2 (RP2)
Updated test provides rapid results for SARS-CoV-2 and other important respiratory pathogens and a simplified workflow CARLSBAD, Calif. , June 29, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems,
View HTML
Toggle SummaryJune 16, 2020 GenMark Diagnostics Chosen as Primary Provider of Rapid Diagnostic Testing for Vidant Health
Largest health system in eastern North Carolina turns to ePlex® platform for fast results on SARS-CoV-2, respiratory and blood stream infections CARLSBAD, Calif. , June 16, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular
View HTML
Toggle SummaryMay 27, 2020 GenMark Diagnostics to Participate in Upcoming Investor Conferences
CARLSBAD, Calif. , May 27, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality
View HTML
Toggle SummaryMay 11, 2020 GenMark Diagnostics Announces Closing of $80 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
CARLSBAD, Calif. , May 11, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality
View HTML
Toggle SummaryMay 6, 2020 GenMark Prices Public Offering of Common Stock
CARLSBAD, Calif. , May 06, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality
View HTML
Toggle SummaryMay 6, 2020 GenMark Commences Public Offering of Common Stock
CARLSBAD, Calif. , May 06, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality
View HTML
Toggle SummaryMay 4, 2020 GenMark Diagnostics Reports First Quarter 2020 Results
CARLSBAD, Calif. , May 04, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. ("GenMark" or the "Company") (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended March 31, 2020 .
View HTML
Toggle SummaryMay 4, 2020 GenMark Diagnostics Announces Scott Mendel Appointed CEO
CARLSBAD, Calif. , May 04, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that Scott Mendel has been appointed President and Chief Executive Officer effective immediately.
View HTML
Toggle SummaryApril 22, 2020 GenMark Diagnostics to Report First Quarter 2020 Financial Results on May 4, 2020
CARLSBAD, Calif. , April 22, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its first quarter earnings results after market close on Monday, May 4, 2020. Management will hold a conference call to review the company's financial performance
View HTML
Toggle SummaryApril 7, 2020 GenMark Diagnostics Provides Preliminary Financial and Operational Results for First Quarter 2020 and Increases 2020 Revenue Guidance
First Quarter 2020 Revenue Expected to Represent Approximately 80% Year-Over-Year Growth CARLSBAD, Calif. , April 07, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary
View HTML